| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/03/2006 | CN1765376A Application of H. seniavinii in preparation of weight-reducing food |
| 05/03/2006 | CN1765375A Application of H. seniavinii in preparation of food for resisting depression or/and promoting memory for learning |
| 05/03/2006 | CN1765374A Preparation method of ganoderma lucidum chewable tablet and product |
| 05/03/2006 | CN1765225A Insomnia treating nutrition porridge |
| 05/03/2006 | CN1254478C Derivatives of monosaccharides as well adhesion inhibitors |
| 05/03/2006 | CN1254476C Dihydroimidazo[5,1-a]-beta-carboline derivatives, method for preparing same and use thereof as medicine |
| 05/03/2006 | CN1254475C 5-methoxy-8-aryl-[1,2,4]triazolo[1,5-a]pyridine derivatives as adenosine receptor antagonists |
| 05/03/2006 | CN1254474C Tetrahydroazepine derivatives useful as dopamine d3 receptor modulators (antipsychotic agents) |
| 05/03/2006 | CN1254469C Arylsulfonyl derivatives with 5-HT6 receptor affinity |
| 05/03/2006 | CN1254272C Activation and inhibition of immune system |
| 05/03/2006 | CN1254263C Chinese medicine composition for treating senile dementia |
| 05/03/2006 | CN1254251C Composition of pharmaceutical and preparation process thereof |
| 05/03/2006 | CN1254234C Plasmid DNA (Lipogenes TM) and encapsulating therapeutica agent containing karyon-positioning signal /fusion-promoting peptide conjugate into targeted liposomes complex |
| 05/02/2006 | US7038077 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives; nervous system, psychological, and psychiatric disorders |
| 05/02/2006 | US7038061 Analgesics; anesthetics; antiinflammatory agents; central nervous system duisorders; strokes; antiarthritic agents; inflammatory bowel disorders |
| 05/02/2006 | US7038055 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies |
| 05/02/2006 | US7038052 Process for the synthesis of derivatives of 2, 3-dihydro-1, 4-dioxino- [2, 3-f] quinoline |
| 05/02/2006 | US7037935 4-Pyrrolidino-phenyl-benzyl ether derivatives |
| 05/02/2006 | US7037929 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 05/02/2006 | US7037927 Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| 05/02/2006 | US7037926 Anticarcinogenic, antiallergen, and antiinflammatory agents; autoimmuned diseases |
| 05/02/2006 | US7037925 for treating or preventing organ transplant rejection, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes, asthma, rhinitis, atopic dermatitis, autoimmune disorders, Alzheimer's disease, leukemia |
| 05/02/2006 | US7037918 Antidiabetic agents, cardiovascular disorders, Alzheimer's disease, nervous system disorders |
| 05/02/2006 | US7037899 Derivatives of 2-3-O- isopropylidene- alpha -L-xylo-2-hexulofuranosonic acid, useful for treating inflammatory and autoimmune diseases |
| 05/02/2006 | US7037896 HIV inhibiting peptide (VIRIP) and amidated, acetylated, sulfated, polyethylene glycol modified, phosphorylated and/or glycosylated derivatives |
| 05/02/2006 | US7037719 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| 05/02/2006 | US7037709 Comprises nucleotide sequences coding microsomal enzymes for detoxification of xenobiotic compounds in liver; drug screening; gene therapy |
| 05/02/2006 | US7037665 Compositions comprising SNORF36 receptor compounds |
| 05/02/2006 | US7037533 Functional agent for decomposing nicotine and method of preparing the same |
| 05/02/2006 | US7037495 Antimicrobial compositions |
| 05/02/2006 | CA2354877C Method for the preparation of citalopram |
| 05/02/2006 | CA2334012C 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors |
| 05/02/2006 | CA2326804C Compounds with activity on muscarinic receptors |
| 05/02/2006 | CA2191843C The preparation of nalbuphine having low levels of beta-epimer |
| 05/02/2006 | CA2174544C Method for using pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines as adrenergic agents |
| 05/02/2006 | CA2173974C Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| 05/02/2006 | CA2061836C Nmda antagonists |
| 04/27/2006 | WO2006044958A1 Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists |
| 04/27/2006 | WO2006044955A1 Phosphodiesterase 4 inhibitors |
| 04/27/2006 | WO2006044903A1 HYDRATE OF N-METHYL-N-(3-{3-[2-THIENYLCARBONYL]-PYRAZOL-[1,5-α]- PYRAMIDIN-7-YL}PHENYL)ACETAMIDE AND PROCESSES AND METHODS RELATED THERETO |
| 04/27/2006 | WO2006044687A2 Kinase inhibitors |
| 04/27/2006 | WO2006044682A1 Compounds for nonsense suppression, and methods for their use |
| 04/27/2006 | WO2006044528A1 Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| 04/27/2006 | WO2006044472A1 Carbamate compounds for use in treating neurodegenerative disorders |
| 04/27/2006 | WO2006044454A1 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists |
| 04/27/2006 | WO2006044412A1 Novel b1 bradykinin receptor antagonists |
| 04/27/2006 | WO2006044379A2 Novel curcumin analogues and uses thereof |
| 04/27/2006 | WO2006044228A1 Histamine h3 receptor inhibitors, preparation and therapeutic uses |
| 04/27/2006 | WO2006044115A2 Method of treating parkinson's disease by convection-enhanced infusion of glial cell-line derived neurotrophic factor (gdnf) to the putamen |
| 04/27/2006 | WO2006043800A1 Use of memantine for the prevention of neurotoxic reactions caused by antileukemic chemotherapy |
| 04/27/2006 | WO2006043710A1 Drug development target protein and target gene, and method of screening |
| 04/27/2006 | WO2006043671A1 TRANSCRIPTIONAL FACTOR Nrf2 ACTIVATOR AND FOOD HAVING THE FUNCTION OF THE SAME IMPARTED THERETO |
| 04/27/2006 | WO2006043532A1 Therapeutic agent for parkinson's disease |
| 04/27/2006 | WO2006043518A1 Drug for treating neurological disease |
| 04/27/2006 | WO2006043064A1 Piperidines and related compounds for treatment of alzheimer's disease |
| 04/27/2006 | WO2006042638A1 3,6-substituted 5-arylamino-1h-pyidine-2-one derivatives and related compounds as poly(adp-ribose)polymerase (parp) inhibitors in the treatment of tissue damage or disease caused by necrosis or apoptosis |
| 04/27/2006 | WO2006042479A1 Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salt and coffeine |
| 04/27/2006 | WO2006042440A1 Pharmaceutical canscora diffusa-containing composition |
| 04/27/2006 | WO2006042406A1 Method for modification of ϝ-secretase activity through inhibition of fkbp13 |
| 04/27/2006 | WO2006042396A1 Modulation of neuroglia-derived bdnf in the treatment and prevention of pain |
| 04/27/2006 | WO2006042362A1 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms |
| 04/27/2006 | WO2006023396A3 Vla-4 antagonists |
| 04/27/2006 | WO2006021412A3 Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
| 04/27/2006 | WO2006012256A3 Fkbp binding composition and pharmaceutical use thereof |
| 04/27/2006 | WO2005120570A3 Therapeutic targeting of parc/ccl18 and its signaling in pulmonary fibrosis |
| 04/27/2006 | WO2005113586A3 Disease-associated proteins |
| 04/27/2006 | WO2005101004A3 Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1) |
| 04/27/2006 | WO2003040333A3 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof |
| 04/27/2006 | US20060089404 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 04/27/2006 | US20060089394 {[2-Methyl-4-({[4'-(trifluoromethyl)-3-biphenylyl]methyl}thio)phenyl]oxy}acetic acid; adipogenic signalling cascade and lipid homeostasis; increase High Density Lipoproteins; hypotensive agent; Syndrome X, obesity, insulin resistance, cardiovascular disorder |
| 04/27/2006 | US20060089393 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
| 04/27/2006 | US20060089380 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) |
| 04/27/2006 | US20060089372 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine |
| 04/27/2006 | US20060089368 Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
| 04/27/2006 | US20060089366 New piperazine and piperidine compounds |
| 04/27/2006 | US20060089365 Heterocyclic compounds useful as nurr-1 activators |
| 04/27/2006 | US20060089356 Substituted imidazoles as cannabinoid receptor modulators |
| 04/27/2006 | US20060089355 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides |
| 04/27/2006 | US20060089353 Indole derivative compounds and drugs containing the compounds as the active ingredient |
| 04/27/2006 | US20060089346 Optionally fused aryl-substituted azepanones, oxazepanone or thiazepanones substituted with a dipeptide group, e.g., N2-[(3,5-difluorophenyl)acetyl]-N1-[(2R,3R)-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide; secretase inhibitors for treating Alzheimer's disease |
| 04/27/2006 | US20060089345 Indole derivatives, method for preparating same and pharmaceutical compositions containing same |
| 04/27/2006 | US20060089344 E.g., 2-(Methylamino)-2-oxoethyl 3-[1-(1-isoquinolyl)-4-piperidyl]propylcarbamate hydrochloride and 3{2-[1-(2-quinolyl)-4-piperidyl]-ethyl}-1,3-oxazolidine-2,4-dione; preventing or treating a pathology in which endogenous cannabinoids and/or any other substrate metabolized by the enzyme FA; analgesics |
| 04/27/2006 | US20060089336 4-Dedimethylamino tetracycline compounds |
| 04/27/2006 | US20060089334 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 04/27/2006 | US20060089312 Protease inhibitors |
| 04/27/2006 | US20060088932 Truncated glycogen synthase kinase 3 crystallizable polypeptide; drug screening for Alzheimer's Disease treatments, antidiabetic and antiinflammatory agents |
| 04/27/2006 | US20060088915 A G protein-coupled receptor protein for the treatment of digestive diseases |
| 04/27/2006 | US20060088913 Mutation associated with epilepsy |
| 04/27/2006 | US20060088890 Identification and isolation of somatic stem cells and uses thereof |
| 04/27/2006 | US20060088881 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules |
| 04/27/2006 | US20060088835 Schizophrenia associated genes |
| 04/27/2006 | US20060088827 Diagnostic and therapeutic use of a voltage-gated ion channel scn2a for neurodegenerative diseases |
| 04/27/2006 | US20060088820 Detecting superantigen activity in a biological sample |
| 04/27/2006 | US20060088548 Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
| 04/27/2006 | US20060088535 Method for enhancing long-term memory in a subject and uses thereof |
| 04/27/2006 | US20060088529 Bispecific monoclonal antibodies to IL-12 and IL-18 |
| 04/27/2006 | US20060088520 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| 04/27/2006 | DE102004051014A1 Chemisch modifizierte Peptidanaloga Chemically modified peptide analogs |
| 04/27/2006 | DE10164687B4 Crystalline citalopram base and salts with high purity useful for treatment of depression |
| 04/27/2006 | CA2584854A1 Carbamate compounds for use in treating neurodegenerative disorders |